Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$16000.0.

  • Regenxbio's Change in Accured Expenses fell 10032.78% to -$16000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.4 million, marking a year-over-year decrease of 38807.38%. This contributed to the annual value of -$12.1 million for FY2024, which is 38206.76% down from last year.
  • Per Regenxbio's latest filing, its Change in Accured Expenses stood at -$16000.0 for Q3 2025, which was down 10032.78% from $11.5 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Change in Accured Expenses ranged from a high of $29.4 million in Q4 2021 and a low of -$26.5 million during Q1 2022
  • Its 5-year average for Change in Accured Expenses is -$701789.5, with a median of $121000.0 in 2023.
  • As far as peak fluctuations go, Regenxbio's Change in Accured Expenses skyrocketed by 304350.0% in 2021, and later crashed by 791322.31% in 2024.
  • Over the past 5 years, Regenxbio's Change in Accured Expenses (Quarter) stood at $29.4 million in 2021, then tumbled by 91.08% to $2.6 million in 2022, then plummeted by 95.39% to $121000.0 in 2023, then crashed by 7913.22% to -$9.5 million in 2024, then soared by 99.83% to -$16000.0 in 2025.
  • Its last three reported values are -$16000.0 in Q3 2025, $11.5 million for Q2 2025, and -$14.5 million during Q1 2025.